Abstract
The fetal inflammatory response (FIR) increases the risk of perinatal brain injury, particularly in extremely low gestational age newborns (ELGANs, < 28 weeks of gestation). One of the mechanisms contributing to such a risk is a postnatal intermittent or sustained systemic inflammation (ISSI) following FIR. The link between prenatal and postnatal systemic inflammation is supported by the presence of well-established inflammatory biomarkers in the umbilical cord and peripheral blood. However, the extent of molecular changes contributing to this association is unknown. Using RNA sequencing and mass spectrometry proteomics, we profiled the transcriptome and proteome of archived neonatal dried blood spot (DBS) specimens from 21 ELGANs. Comparing FIR-affected and unaffected ELGANs, we identified 783 gene and 27 protein expression changes of 50% magnitude or more, and an experiment-wide significance level below 5% false discovery rate. These expression changes confirm the robust postnatal activation of the innate immune system in FIR-affected ELGANs and reveal an impairment of their adaptive immunity. In turn, the altered pathways provide clues about the molecular mechanisms triggering ISSI after FIR, and the onset of perinatal brain injury.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Spanish MINECO/FEDER (TIN2015-71079-P). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS Omics Tech) and is a member of Proteored, PRB3, which is supported by grant PT17/0019 of the PE I+D+i 2013-2016, funded by ISCIII and ERDF. We acknowledge support from the Spanish Ministry of Economy and Competitiveness, ?Centro de Excelencia Severo Ochoa 2013-2017? (SEV-2012-0208), ?Unidad de Excelencia Maria de Maeztu? (MDM-2014-0370), and “Secretaria d’Universitats i Recerca del Departament d?Economia i Coneixement de la Generalitat de Catalunya? (SGR17-595; SGR17-1020).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
NA
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
The transcriptomics and clinical data reported in this paper are available through the European Genome-phenome Archive (EGA) under accession number EGAS00001003635. The mass spectrometry proteomics data are available through the PRIDE repository under accession number PXD011626.
